Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines

BACKGROUND: Despite the large-scale clinical application of programmed death-ligand 1 (PD-L1) monoclonal antibody, reduction in its clinical response rate has become a gradual problem. As such, use of PD-L1 monoclonal antibody in combination with other anticarcinoma drugs has been the main strategy...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Qian, Wu, Changping, Chen, Jianping, Wang, Weibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381951/
https://www.ncbi.nlm.nih.gov/pubmed/32724815
http://dx.doi.org/10.1155/2020/8910183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381951/
https://www.ncbi.nlm.nih.gov/pubmed/32724815
http://dx.doi.org/10.1155/2020/8910183

Ejemplares similares